Roth Capital Starts Pieris Pharmaceuticals (PIRS) at Buy

Roth Capital initiates coverage on Pieris Pharmaceuticals (NASDAQ: PIRS) with a Buy rating and a price target of $7.00.

Analyst Elemer Piros commented, "We are initiating coverage of Pieris Pharmaceuticals with a Buy rating and 12-month target price of $7/share. Pieris secured monopoly to an entire biologic drug class, allowing the company to develop a multitude of treatments."

For an analyst ratings summary and ratings history on Pieris Pharmaceuticals click here. For more ratings news on Pieris Pharmaceuticals click here.

Shares of Pieris Pharmaceuticals closed at $2.70 yesterday.

You May Also Be Interested In

• Stifel Starts Sutro Biopharma (STRO) at Buy
• TD Cowen Starts Obsidian Therapeutics (OBX) at Buy
• Global Ship Lease Inc. (GSL) PT Raised to $50 at Jefferies, 'We remain bullish on the 15-vessel newbuild program'